The role of prolactin аnd dopamine in the pathogenesis of endometriosis

Abstract

Background: to consider the modern ideas of a role of prolactin and dopamine in a pathogenesis of the endometriosis and possibility to apply of agonists of dopamine in disease,s therapy. Materials: literary data of foreign and native authors from 1972 for 2015. Methods: systematic analysis and synthesis of publications. Conclusion: Carrying out further researches of a role of prolactin and dopamine in a pathogenesis of endometriosis and multicenter supervision is necessary for confirmation of safety and effectiveness of therapy by dopamine agonists.

Keywords

genitalendometriosis / prolactin / dopamine agonists

References

[1] Дзеранова Л.К., Табеева К.И., Гончаров Н.П. Макропролактинемия // Проблемы репродукции. - 2005. - № 2. - C. 60-65. [Dzeranova LK, Tabeeva KI, Goncharov NP. Makroprolaktinemija. Problemy reprodukcii. 2005;2:60-5. (In Russ).]

[2] Иловайская И.А., Марова Е.И. Биология пролактина. Нейроэндокринный контроль и регуляция секреции // Акушерство и гинекология. - 2000. - № 5. - C. 42-46. [Ilovajskaja IA, Marova EI. Biologija prolaktina. Nejrojendokrinnyj kontrol’ i reguljacija sekrecii. Akusherstvo i ginekologija. 2000;5:42-6. (In Russ).]

[3] Дедов И.И., Мельниченко Г.А., Романцева Т.И. Синдром гиперпролактинемии. - М.: Триада-Х, 2004. - 304 с. [Dedov II, Mel’nichenko GA, Romanceva TI. Sindrom giperprolaktinemii. Moscow: Triada-H; 2004. (In Russ).]

[4] Hwang P, Guyda H, Friesen H. Purification of human prolactin. J Biol Chem. 1972;247:1955-58.

[5] Fuxe K, Hо¨kfelt T, Eneroth P, et al. Prolactin-like immunoreactivity: localization in nerve terminals of rat hypothalamus. Science. 1977;196:899-900.

[6] Дзеранова Л.К., Табеева К.И. Успехи, проблемы и перспективы изучения пролактина // Российский химический журнал. - 2005. - № 1. - C. 84-93. [Dzeranova LK, Tabeeva KI. Uspehi, problemy i perspektivy izuchenija prolaktina. Rossijskij himicheskij zhurnal. 2005;1:84-93. (In Russ).]

[7] Гилязутдинов И.А., Гилязутдинова З.Ш. Нейроэндокринная патология в гинекологии и акушерстве: руководство для врачей. - М.: МЕДпресс-информ, 2008. - 432 с. [Giljazutdinov IA, Giljazutdinova ZSh. Nejrojendokrinnaja patologija v ginekologii i akusherstve: Rukovodstvo dlja vrachej. Moscow: MEDpress-inform; 2008. (In Russ).]

[8] Clapp C, Thebault S, Jeziorski MC. Peptide Hormone Regulation of Angiogenesis, Physiol Rev. 2009;89:1177-215.

[9] Struman I, Bentzien F, Lee HY, et al. Opposing actions of intact and N-terminal fragments of the human prolactin growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA. 1999;96:1246-51.

[10] Grattan DR, Kokay IC. Prolactin: A Pleiotropic Neuroendocrine Hormone. J of Neuroendocrinology. 2008; 20:752-63.

[11] Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. - 2-е изд. - М.: ГЭОТАР-Медиа, 2009. - 432 с. [Dedov II, Mel’nichenko GA, Fadeev VV. Jendokrinologija. 2nd ed. Moscow: GJeOTAR-Media; 2009. (In Russ).]

[12] Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. - 3-е изд. - М.: МЕДпресс-информ, 2008. - 528 с. [Serov VN, Prilepskaja VN, Ovsjannikova TV. Ginekologicheskaja jendokrinologija. 3nd ed. Moscow: MEDpress-inform; 2008. (In Russ).]

[13] Canfield J, Sivaprasad U, Brooks LC. Mechanism for ordered receptor binding by human prolactin. Biochemistry. 2004;43(2):13755-65.

[14] Панков Ю.А. Новые системы проведения сигналов в механизмах гормональной регуляции // Проблемы эндокринологии. - 2000. - № 2. - C. 3-8. [Pankov JA. Novye sistemy provedenija signalov v mehanizmah gormonal’noj reguljacii. Problemy jendokrinologii. 2000;2:3-8. (In Russ).]

[15] Freeman ME, Kanycska B, Lerant A, et al. Prolactin: Structure, Function, and Regulation of Secretion. Physiol Rev. 2000;80(4):1523-631.

[16] Гинекология от пубертата до постменопаузы: практическое руководство для врачей / ред. Э.К. Айламазян. - М.: МЕДпресс-информ, 2007. - 512 с. [Ajlamazjan JK, red. Ginekologija ot pubertata do postmenopauzy: prakticheskoe rukovodstvo dlja vrachej. Moscow: MEDpress-inform; 2007. (In Russ).]

[17] Missale C, Russel S, Robinson SW, et al. Dopamine Receptors: From Structure to Function. Physiological Reviews. 1998;1:189-225.

[18] Kebabian JW, Caine DB. Multiple receptors for dopamine. Nature. 1979;277:93-96.

[19] Nilsson C, Eriksson E. Partial dopamine D2 receptor agonists antagonize prolactin-regulating D2 receptors in a transfected clonal cell line (GH4ZR7). Eur J Pharmacol. 1992;218:205-11.

[20] Фаттахова Ф.А. Значение шишковидной железы в нейроэндокринном гомеостазе женщины // Казанский медицинский журнал. - 1987. - Т. 68. - № 2. - C. 121-24. [Fattahova FA. Znachenie shishkovidnoj zhelezy v nejrojendokrinnom gomeostaze zhenshhiny. Kazanskij medicinskij zhurnal. 1987;68(2): 12-24. (In Russ).]

[21] Арушанян Э.Б., Арушанян Л.Г. Модуляторные свойства эпифизарного мелатонина // Проблемы эндокринологии. - 1991. - № 3. - C. 65-68. [Arushanjan JB, Arushanjan LG. Moduljatornye svojstva jepifizarnogo melatonina. Problemy jendokrinologii. 1991;3:65-8. (In Russ).]

[22] Мельниченко Г.А., Марова Е.И., Дзеранова Л.К., Вакс В.В. Гиперпролактинемия у женщин и мужчин: пособие для врачей. - М., 2007. - 56 с. [Mel’nichenko GA, Marova EI, Dzeranova LK, Vaks VV. Giperprolaktinemija u zhenshhin i muzhchin. Posobie dlja vrachej. Moscow; 2007. (In Russ).]

[23] Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. - М.: МИА, 2002. - 591 с. [Smetnik VP, Tumilovich LG. Neoperativnaja ginekologija: rukovodstvo dlja vrachej. Moscow: MIA; 2002. (In Russ).]

[24] Ахкубекова Н.Н. Взаимодействие эстрогенов, прогестерона и дофамина в регуляции секрециипролактина // Проблемы эндокринологии. - 2009. - Т. 55. - № 6 - C. 46-8. [Ahkubekova NN. Vzaimodejstvie jestrogenov, progesterona i dofamina v reguljacii sekrecii prolaktina. Problemy jendokrinologii. 2009;55(6):46-8. (In Russ).]

[25] Adamson AD, Friedrichsen S. Human prolactin gene promoter regulation by estrogen: Covergence with tumor necrosis factor-a signaling. Endocrinology. 2008;2:687-94.

[26] Vinatier D, Orazi G, Cosson M, Dufour P. Theories of endometriosis. Europ J Obstet Gynecol Reprod Biology. 2001;96(1):21-34.

[27] Ярмолинская М.И. Генитальный эндометриоз: влияние гормональных, иммунологических и генетических факторов на развитие, особенности течения и выбор терапии: автореф. дис. … д-ра мед. наук. - СПб., 2009. - 42 с. [Jarmolinskaja MI. Genital’nyj jendometrioz: vlijanie gormonal’nyh, immunologicheskih i geneticheskih faktorov na razvitie, osobennosti techenija i vybor terapii [dissertation]. Saint Petersburg; 2009. (In Russ).]

[28] Hayashi N, Taketani Y, Mizuno M. Relationship between luteal function and prolactin in infertile women with endometriosis. Nippon Sanka Fujinka Gakkai Zasshi. 1989;41:1720.

[29] Moeloek FA, Moegny E. Endometriosis and luteal phase defect. Asia Oceania J Obstet Gynecol. 1993;19:171-176.

[30] He Ye. Prolactin secretion in patients with endometriosis and its relationship to luteal phase defect and infertility. Zhonghua fu Chan ke Za Zhi. 1993;28:14-7.

[31] Gregorion G, Bakes P, Vitoratos N, et al. Evaluation serum prolactin levels in patients with endometriosis and infertility. Gynecol Obstet Invest. 1999;48: 48-51.

[32] Panidis D, Vavilis D, Rousso D, et al. Provocative tests of prolactin before, during and after long-term Danazol treatment in patients with endometriosis. Gynecol Endocrinol. 1992;6:19-24.

[33] Machida T, Taga M, Minaquchi H. Prolactin secretion in endometriotic patients. Eur J Obstet Gynecol Reprod Biol. 1997;72:89-92.

[34] Arumugam K. Serum prolactin levels in infertile patients with endometriosis. Malays J Pathol. 1991;13:43-5.

[35] Lima AP, Moura MD, Rosa A.M, Silva. Prolactin and cortisol levels in women with endometriosis. Braz J Med Biol Res. 2006;39(8):1121-7.

[36] Cunha-Filho JS, Gross JL, Lemos NA, et al. Hyperprolactinemia and luteal insufficiency in infertile patients with mild and minimal endometriosis. Horm Metab Res. 2001;33:216-20.

[37] Cunha-Filho JS, Gross JL, Lemos NA, et al. Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild Endometriosis. Hum Reprod. 2002;17(4):960-5.

[38] Muse K, Wilson EA, Jawal MJ. Prolactin hyperstimulation in response to thyrotropin-releasing hormone in patients with endometriosis. Fertil Steril. 1982;38:419-22.

[39] Bilibio JP, Souza CAB, Rodini GP, et al. Serum Prolactin and CA-125 Levels as Biomarkers of Peritoneal Endometriosis. Gynecol Obstet Invest. 2014;78:45-52.

[40] Cramer D, Epidemiology of Endometriosis. In: Wilson EA, ed. Endometriosis. New York: Alan R. Liss Inc.; 1987. P. 43-4.

[41] Haney AF, Handwerger S, Weinberg JB. Peritoneal fluid prolactin in infertile women with endometriosis: lack of evidence of secretory activity by endometrial implants. Fertil Steril. 1984;40:935-8.

[42] Chew P, Peh KL, Loganath A, et al. Elevated peritoneal fluid luteinizing hormone and prolactin concentrations in infertile women with endometriosis. Int J Gynecol Obstet. 1990;33:35-9.

[43] Radwanska E, Heing I, Dmowski WP. Nocturnal prolactin levels in infertile women with endometriosis. J Reprod Med. 1987;32:605-8.

[44] Ben-Jonathon N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions and clinical aspects. Endocr Rev. 1996;17:639-69.

[45] Maaskant RA, Bogic LV, Gilger S, et al. The human prolactin receptor in the fetal membranes, decidua, and placenta. J Clin Endocrinol Metab. 1996;81:396-405.

[46] Tseng L, Zhu HH. Progestin induces prolactin receptor in human endometrial stromal cells. J Soc Gynecol Invest. 1998;5:149-55.

[47] Jones RL, Critchley HOD, Brooks J, et al. Localization and temporal expression of prolactin receptor in human endometrium. J Clin Endocrinol Metab. 1998;83:258-62.

[48] Martinez LB, Leyva MZ, Romero IC. Prolactin receptor in human endometriotic tissues. Acta Obstet Gynecol Scand. 2002;81(1):5-10.

[49] Novella-Maestre E, Carda C, Ruiz-Sauri A, et al. Identification and Quantification of Dopamine Receptor 2 in Human Eutopic and Ectopic Endometrium: A Novel Molecular Target for Endometriosis Therapy. Biology of Reproduction. 2010;83: 866-73.

[50] Basu S, Sarkar C, Chakroborty D, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 2004;64:5551-55.

[51] Soares SR, Martinez-Varea A, Hidalgo-Mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril. 2012;98(3).

[52] Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol. 2007;21(5):1066-81.

[53] Matsuzaki S, Canis M, Murakami T, et al. Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis. Fertil Steril. 2001;76:712-16.

[54] Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod. Update. 2007;13:331-42.

[55] Malaguarnera L, Imbesi RM, Scuto A, et al. Prolactin increases HO-1 expression and induces VEGF production in human macrophages. J Cell Biochem. 2004;93:197-206.

[56] Secretion of Prolactin Following Three Dimensional Culture of Human Endometrial Tissue. Shiraz E-Medical Jl. 2009;10(1):4-11.

[57] Donnez J, Smoes P, Gillerot S, et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998;13:1686-90.

[58] Machado DE, Abrao MS, Berardo PT, et al. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril. 2008;90(1):148-55.

[59] Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009;24(5):1025-35.

[60] Delgado-Rosas F, Gomez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction. 2011;142:745-55.

[61] Ercan CM, Kayaalp O, Cengiz M, et al. Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model. Arch Gynecol Obstet. 2015;291(5):1103-11.

[62] Gomez R, Abad A, Delgado F, et al. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril. 2011;95(3):882-88.

[63] Hamid AM, Madkour WA, Moawad A, et al. Does Cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. Arch Gynecol Obstet. 2014;290(4): 677-82.

RIGHTS & PERMISSIONS

Suslova E.V., Yarmolinskaya M.I., Potin V.V.